Lupin’s Luforbec Launch Leads UK Respiratory Efforts
Lupin UK General Manager Ben Ellis Sets Out Strategy For Fostair Rival
Following Lupin’s launch of the first UK generic version of Fostair in August, Lupin UK general manager Ben Ellis tells Generics Bulletin how the company is taking full advantage of the opportunity and laying the groundwork for future activities in the respiratory arena.
You may also be interested in...
Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.
As 2021 drew to a close, there was no shortage of exciting developments for the off-patent industry. Alongside news of a strategic review affecting one of the biggest generics and biosimilars players, Generics Bulletin also held its annual Global Generics & Biosimilars Awards and brought readers fresh and exclusive insights from top industry executives.
A continuing lack of legal certainty continues to plague suppliers to the Northern Ireland market despite the latest proposals from the EU Commission, UK and European off-patent industry leaders Mark Samuels and Adrian van den Hoven tell Generics Bulletin.